[D-Lys⁶]-LH-RH 

LH-RH agonist. It has been conjugated to cytotoxic compounds such as methotrexate (MTX), doxorubicin (DOX), and glutaryl-2-(hydroxymethyl)anthraquinone (G-HMAQ), and together with other conjugated LH-RH analogs comprise a class of targeted chemotherapeutic agents for cancers expressing receptors for LH-RH.

≥95% (HPLC)

powder

−20°C

Krebs, L.J., et al., Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Cancer Res. 60, 4194-4199, (2000) abstract

Rekasi, Z., et al., Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system. Endocrinology 132, 1991-2000, (1993) abstract

Nikolics, K., et al., Decreased in vitro LH releasing activity of oligomeric LH-RH derivatives. Endocrinol. Exp. 18, 109, (1984) abstract

3